Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma

Gene Therapy

Volumn 5, Issue 7, 1998, Pages 975-983

  Hirschowitz, E A ^a   Leonard, S ^a   Song, W ^a   Ferris, B ^a   Leopold, P L ^a   Lewis, J J ^b   Bowne, W B ^b   Wang, S ^b   Houghton, A N ^b   Crystal, R G ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adenovirus; Antigen; gp75; IL2; Melanoma; Vaccine

Indexed keywords

CD4 ANTIGEN; COMPLEMENTARY DNA; DIFFERENTIATION ANTIGEN; DNA VACCINE; INTERLEUKIN 2; MELANOMA ANTIGEN; PROTEIN;

ADENOVIRUS; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; EXPRESSION VECTOR; IMMUNOTHERAPY; LUNG METASTASIS; MELANOCYTE; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL; VIRUS EXPRESSION;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; MURINAE;

EID: 7344243181     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300668     Document Type: Article

References (83)

1. Mukherji B, Chakraborty NG. Immunobiology and immunotherapy of melanoma. Curr Opin Oncol 1995; 7: 175-184.
2. Rankin EM. Scientific aspects of gene therapy in melanoma. Curr Opin Oncol 1995; 7: 192-196.
3. Real FX et al. Class 1 (unique) tumor antigens of human melanoma: identification of unique and common epitopes on a 90-kDa glycoprotein. Proc Natl Acad Sci USA 1988; 85: 3965-3969.
4. van der Bruggen P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-1647.
5. Traversari C et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HAL-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992; 176: 1453-1457.
6. Brichard V et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993; 178: 489-495.
7. Zakut R et al. Differential expression of mage-1, -2, and -3 messenger RNA in transformed and normal human cell lines. Cancer Res 1993; 53: 5-8.
8. Bakker AB et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994; 179: 1005-1009.
9. Gaugler B et al. Human gene mage-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994; 179: 921-930.
10. Kawakami Y et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994; 91: 3515-3519.
11. Kawakami Y et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994; 91: 6458-6462.
12. van der Bruggen P et al. A peptide encoded by human gene mage-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing mage-3. Eur J Immunol 1994; 24: 3038-3043.
13. Wolfel T et al. A p16ink4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269: 1281-1284.
14. Fleischhauer K et al. Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen melan-a/mart-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line. J Immunol 1996; 157: 787-797.
15. Livingston PO et al. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 1987; 84: 2911-2915.
16. Estin CD et al. Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. Proc Natl Acad Sci USA 1988; 85: 1052-1056.
17. Morton DL et al. Active specific immunotherapy in malignant melanoma. Semin Surg Oncol 1989; 5: 420-425.
18. Bystryn JC. Tumor vaccines. Cancer Metastasis Rev 1990; 9: 81-91.
19. + T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J Immunol 1991; 146: 3235-3241.
20. McGee JM. Immunotherapy for malignant melanoma: a review and update. Semin Surg Oncol 1991; 7: 217-220.
21. Morton DL et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216: 463-482.
22. Chapman PB, Houghton AN. Non-antibody immunotherapy of cancer. Curr Opin Immunol 1993; 5: 726-731.
23. Crowley NJ, Seigler HF. Possibilities of immunotherapy and gene therapy for malignant melanoma. Semin Surg Oncol 1993; 9: 273-278.
24. Pardoll DM. New strategies for enhancing the immunogenicity of tumors. Curr Opin Immunol 1993; 5: 719-725.
25. D3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res 1994; 54: 197-203.
26. Tepper RI, Mule JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994; 5: 153-164.
27. Aichele P et al. 1 cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med 1995; 182: 261-266.
28. Bakker AB et al. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 1995; 55: 5330-5334.
29. Barth A, Morton DL. The role of adjuvant therapy in melanoma management. Cancer 1995; 75: 726-734.
30. Hoon DS, Yuzuki D, Hayashida M, Morton DL. Melanoma patients immunized with melanoma cell vaccine induced antibody responses to recombinant mage-1 antigen. J Immunol 1995; 154: 730-737.
31. Kitamura K et al. Serological response patterns of melanoma patients immunized with a gm2 ganglioside conjugate vaccine. Proc Natl Acad Sci USA 1995; 92: 2805-2809.
32. Miller K et al. Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 1995; 75: 495-502.
33. Morioka N et al. Cytotoxic T cell recognition of a human melanoma derived peptide with a carboxyl-terminal alanine-proline sequence. Mol Immunol 1995; 32: 573-581.
34. Mukherji B et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995; 92: 8078-8082.
35. Parmiani G, Colombo MF. Somatic gene therapy of human melanoma: preclinical studies and early clinical trials. Melanoma Res 1995; 5: 295-301.
36. Dalgleish A. The case for therapeutic vaccines. Melanoma Res 1996; 6: 5-10.
37. Hu X et al. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996; 56: 2479-2483.
38. Jaeger E et al. Generation of cytotoxic T cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 1996; 66: 162-169.
39. Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT. New treatment options for patients with melanoma: review of melanoma-derived T cell epitope-based peptide vaccines. Melanoma Res 1996; 6: 11-24.
40. Mastrangelo MJ et al. Active specific immunization in the treatment of patients with melanoma. Semin Oncol 1996; 23: 773-781.
41. Naftzger C et al. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA 1996; 93: 14809-14814.
42. Parkhurst MR et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201 -binding residues. J Immunol 1996; 157: 2539-2548.
43. Rosenberg SA. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Annu Rev Med 1996; 47: 481-491.
44. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996; 56: 4749-4757.
45. + T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol 1996; 157: 4079-4086.
46. Zhai Y et al. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding mart1 or gp100 for cancer therapy. J Immunol 1996; 156: 700-710.
47. Rosenberg SA. Phase I trial in patients with metastatic melanoma of immunization with a recombinant adenovirus encoding the MART-1 melanoma antigen. Office of Recombinant DNA Activities: National Institutes of Health, 1995, RAC No. 9512-140.
48. Vijayasaradhi S, Doskoch PM, Houghton AN. Biosynthesis and intracellular movement of the melanosomal membrane glycoprotein gp75, the human b (brown) locus product Exp Cell Res 1991; 196: 233-240.
49. Vijayasaradhi S, Houghton AN. Purification of an autoantigenic 75-kDa human melanosomal glycoprotein. Int J Cancer 1991; 47: 298-303.
50. Vijayasaradhi S, Bouchard B, Houghton AN. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med 1990; 171: 1375-1380.
51. Wang RF et al. Identification of a gene encoding a melanoma rumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 1995; 181: 799-804.
52. Tai T, Eisinger M, Ogata S, Lloyd KO. Glycoproteins as differentiation markers in human malignant melanoma and melanocytes. Cancer Res 1983; 43: 2773-2779.
53. Mattes MJ, Thomson TM, Old LJ, Lloyd KO. A pigmentation-associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum. Int J Cancer 1983; 32: 717-721.
54. Yokoyama K, Yasumoto K, Suzuki H, Shibahara S Cloning of the human dopachrome tautomerase/tyrosinase-related protein 2 gene and identification of two regulatory regions required for its pigment cell-specific expression. J Biol Chem 1994; 269: 27080-27087.
55. Juillard V et al. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur J Immunol 1995; 25: 3467-3473.
56. Van Ginkel FW et al. Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and beta-galactosidase. Hum Gene Ther 1995; 6: 895-903.
57. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996; 2: 545-550.
58. Yang Y et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Therapy 1996; 3: 137-144.
59. Mack CA et al. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 1997; 8: 99-109.
60. Song W, Kong H-L, Traktman P, Crystal RG. Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenovirus vectors. Hum Gene Ther 1997; 8: 1207-1217.
61. Hara I, Takechi Y, Houghton AN. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 1995; 182: 1609-1614.
62. Chen PW et al. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol 1996; 156: 224-231.
63. Ragot T et al. Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin. J Gen Virol 1993; 74: 501-507.
64. + CTLs in vivo. J Immunol 1995; 155: 2564-2570.
65. Fearon ER et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397-403.
66. Lanzavecchia A. Identifying strategies for immune intervention. Science 1993; 260: 937-944.
67. Dutcher JP et al. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 1989; 7: 477-485.
68. Rosenberg SA et al. Use of rumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. New Engl J Med 1988; 319: 1676-1680.
69. Gansbacher B et al. Interleukin 2 gene transfer into tumor cells abrogates rumorigeniafy and induces protective immunity. J Exp Med 1990; 172: 1217-1224.
70. Karp SE et al. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor. J Immunol 1993; 150: 896-908.
71. Haddada H et al. Adenoviral interleukin-2 gene transfer into p815 tumor cells abrogates tumorigenicity and induces antitumoral immunity in mice. Hum Gene Ther 1993; 4: 703-711.
72. Addison CL et al. Intrarumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA 1995; 92: 8522-8526.
73. Chen SH et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 1995; 92: 2577-2581.
74. Cordier L et al. Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Therapy 1995; 2: 16-21.
75. Parker SE et al. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo. Cancer Gene Ther 1996; 3: 175-185.
76. Qin H, Chatterjee SK. Recombinant vaccinia expressing interleukin-2 for cancer gene therapy. Cancer Gene Ther 1996; 3: 163-167.
77. Toloza EM et al. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther 1996; 3: 11-17.
78. Hirschowitz EA et al. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-denved tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 1995; 6: 1055-1063.
79. Rosenfeld MA et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992; 68: 143-155.
80. Rosenfeld MA et al. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science 1991; 252: 431-434.
81. Thomson TM et al. Pigmentation-associated glycoprotein of human melanomas and melanocytes: definition with a mouse monoclonal antibody. J Invest Dermatol 1985; 85: 169-174.
82. Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature 1980; 283: 139-146.
83. Bouchard B, Vijayasaradhi S, Houghton AN. Production and characterization of antibodies against human tyrosinase J Invest Dermatol 1994; 102: 291-295.